Bayer provides financial support to eligible STIVARGA® (regorafenib) and NEXAVAR® (sorafenib) patients*

Privately Insured*

$0 Co-­Pay Assistance-­A New Level of Support
  • NO monthly cap
  • Up to $25,000 per year
  • Enroll at:
    zerocopaysupport.com
  • Obtain BIN & Group # and
    provide to your pharmacist
  • Call 1.866.581.4992
  • for more information
  • on enrolling online

Government Insured

(eg, Medicare, Medicaid, Military)

  • Information on Part D
    prescription drug plans
  • Financial assistance may be
    available through independent
    charitable organizations
  • Alternate funding options
  • Call 1.866.639.2827
  • to speak with a reimbursement counselor (9 am—5 pm EST/EDT)

Uninsured/Underinsured

  • Patient Assistance Program (PAP)
  • Eligibility requirements apply
  • Up to 12 months of free drug for qualified patients
  • Alternate funding options
  • Call 1.866.639.2827
  • to speak with a reimbursement counselor (9 am—5 pm EST/EDT)

Some insurance plans require patients to obtain approval for coverage before starting therapy (known as Prior Authorization), which can take time and delay the start of therapy. REACH may be able to provide temporary assistance for patients to start therapy right away while waiting for their Prior Authorization approval.

Reach out for help with patient access or support services

Patients taking STIVARGA or NEXAVAR can enroll in REACH® (Resources for Expert Assistance and Care Helpline). This free program is here to support you and your caregivers with information about therapy and financial assistance options.

The REACH program offers:

Nurse Counselors
Nurse counselors to answer your medical questions and provide educational and support materials, as well as guidance on side effects
STIVARGA (regorafenib)  Financial Access Counselors
Financial access counselors to provide help with benefits
  • Benefit verification and specialty pharmacy provider (SPP) identification
  • Patient Assistance Program (PAP) for the uninsured or underinsured
  • Prior authorizations and denial/appeal information
  • Co-pay assistance for eligible commercially insured patients not previously enrolled in the REACH Commercial Co-Pay Assistance Program*
  • Alternative coverage research
    • Referral to independent organizations that may assist eligible patients with their out-of-pocket expenses

Call 1-866-639-2827 or speak to your doctor to REACH your support benefits today.

For more information visit:
Stivarga Logo Link

*Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, and may not participate if this program is prohibited by or conflicts with their private insurance policy, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in Bayer’s Patient Assistance Program are not eligible. Bayer may determine eligibility, monitor participation, equitably distribute product and modify or discontinue any aspect of the REACH program at any time, including but not limited to this commercial co-pay assistance program.

Patients who do or do not meet the requirements for REACH do not automatically qualify for financial help from charitable organizations.

STIVARGA® (regorafenib) INDICATIONS

STIVARGA (regorafenib) is a prescription medicine used to treat people with:

  • colon or rectal cancer that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines
  • a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines

It is not known if STIVARGA is safe and effective in children less than 18 years of age

STIVARGA® (regorafenib) IMPORTANT SAFETY INFORMATION

STIVARGA (regorafenib) can cause liver problems, which can be serious and sometimes lead to death. Your healthcare provider will do blood tests to check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems. Tell your healthcare provider right away if you experience yellowing of your skin or the white part of your eyes, nausea, vomiting, dark urine, or change in your sleep pattern.

Before taking STIVARGA, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems
  • have bleeding problems
  • have high blood pressure
  • have heart problems or chest pain
  • plan to have surgery or have had recent surgery
  • are pregnant or plan to become pregnant. STIVARGA can harm your unborn baby. Females and males with female partners who can become pregnant should use effective birth control during treatment with STIVARGA and for 2 months after their last dose of STIVARGA. Tell your healthcare provider right away if you or your partner becomes pregnant either while taking STIVARGA or within 2 months after your last dose of STIVARGA
  • are breastfeeding or plan to breastfeed. It is not known if STIVARGA passes into your breast milk. Do not breastfeed during treatment with STIVARGA and for 2 weeks after your final dose of STIVARGA.

Tell your healthcare provider about all the prescription and over-the-counter medicines, vitamins, and herbal supplements you take. Avoid drinking grapefruit juice and taking St. John’s wort while taking STIVARGA.

STIVARGA may cause serious side effects, including:

  • severe bleeding. STIVARGA can cause bleeding, which can be serious and sometimes lead to death. Tell your healthcare provider if you have any signs of bleeding while taking STIVARGA, including: vomiting blood or if your vomit looks like coffee grounds, pink or brown urine, red or black (looks like tar) stools, coughing up blood or blood clots, menstrual bleeding that is heavier than normal, unusual vaginal bleeding, nose bleeds that happen often, bruising, and lightheadedness
  • a skin problem called hand-foot skin reaction and severe skin rash. Hand-foot skin reactions are common and sometimes can be severe. Tell your healthcare provider right away if you get redness, pain, blisters, bleeding, or swelling on the palms of your hands or soles of your feet, or a severe rash
  • high blood pressure. Your blood pressure should be checked regularly and any high blood pressure should be treated while you are receiving STIVARGA. Tell your healthcare provider if you have severe headaches, light-headedness, or changes in your vision
  • decreased blood flow to the heart and heart attack. Get emergency help if you have chest pain, have shortness of breath, feel dizzy, or feel like passing out
  • a condition called reversible posterior leukoencephalopathy syndrome (RPLS). Call your healthcare provider right away if you get severe headaches, seizure, confusion, change in vision, or problems thinking
  • a tear in your stomach or intestinal wall (bowel perforation). STIVARGA may cause a tear in your stomach or bowel perforation that can be serious and sometimes lead to death. Contact your healthcare provider immediately if you notice severe pains or swelling in your stomach area (abdomen), high fever, chills, nausea, vomiting, or dehydration
  • wound healing problems. If you need to have a surgical procedure, tell your healthcare provider that you are taking STIVARGA. You should stop taking STIVARGA at least 2 weeks before any planned surgery

The most common side effects with STIVARGA include tiredness, weakness, fatigue; diarrhea (frequent or loose bowel movements); loss of appetite; swelling, pain, and redness of the lining in your mouth, throat, stomach, and bowel (mucositis); voice changes or hoarseness; infection; pain in other parts of your body; weight loss; stomach-area (abdomen) pain; fever; and nausea.

Tell your doctor if you have any side effects that bother you or that do not go away.

For important risk and use information, please see the full Prescribing information for STIVARGA, including Boxed Warning.


NEXAVAR® (sorafenib) INDICATIONS

NEXAVAR is an anticancer medicine used to treat a certain type of liver, kidney or thyroid cancer called:

  • Hepatocellular carcinoma (HCC, a type of liver cancer), when it cannot be treated with surgery
  • Renal cell carcinoma (RCC, a type of kidney cancer)
  • Differentiated thyroid carcinoma (DTC, a type of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing

NEXAVAR has not been studied in children.

NEXAVAR® (sorafenib) IMPORTANT SAFETY CONSIDERATIONS

Do not take NEXAVAR if you have a specific type of lung cancer (squamous cell) and receive carboplatin and paclitaxel or if you are allergic to sorafenib or any of the other ingredients in NEXAVAR.

Before starting NEXAVAR, tell your doctor if you have: allergies, heart problems (including a problem called "congenital long QT syndrome") or chest pain, bleeding or bruising problems, high blood pressure, any planned surgical procedures, lung cancer or are being treated for lung cancer, kidney problems in addition to kidney cancer, or liver problems in addition to liver cancer.

Tell your doctor if you are pregnant or plan to become pregnant and if you are breast-feeding or plan to breast-feed. It is not known if NEXAVAR passes into your breast milk. You and your doctor should decide if you will take NEXAVAR or breast-feed. You should not do both.

NEXAVAR may interact with certain other medicines and cause serious side effects so tell your doctor about all medicines you take including prescription and over-the-counter (OTC) medicines, vitamins, or herbal supplements. Especially tell your doctor if you are taking the following medicines: warfarin (Coumadin, Jantoven® ), neomycin, St. John’s Wort, dexamethasone, phenytoin (Fosphenytoin sodium, Dilantin, Phenytek), carbamazepine (Carbatrol, Equetro, Tegretol, Teril, Epitol), rifampin (Rifater, Rifamate, Rifadin, Rimactane), rifabutin (Mycobutin), phenobarbital.

NEXAVAR may cause serious side effects, including:

  • decreased blood flow to the heart and heart attack. Get emergency help right away and call your doctor if you have chest pain, shortness of breath, feel lightheaded or faint, have nausea or vomiting, or you are sweating a lot.
  • bleeding problems. Bleeding is a common side effect of NEXAVAR that can be serious and sometimes lead to death. Tell your doctor if you have any bleeding or easy bruising while taking NEXAVAR.
  • high blood pressure. High blood pressure is a common side effect of NEXAVAR and can be serious. Your blood pressure should be checked every week during the first 6 weeks of starting therapy and then regularly, thereafter. If your blood pressure is high, it should be treated.
  • a skin problem called hand-foot skin reaction. This causes redness, pain, swelling, or blisters on the palms of your hands and soles of your feet. Your doctor may change your dose or stop treatment for a while.
  • serious skin and mouth reactions. NEXAVAR can cause serious skin and mouth reactions which can be life-threatening. Tell your doctor if you have skin rash, blistering and peeling of the skin, blistering and peeling on the inside of your mouth.
  • an opening in the wall of your stomach or intestines (perforation of the bowel). Tell your doctor right away if you get high fever, nausea, vomiting or abdominal (stomach) pain.
  • birth defects or death of an unborn baby. Avoid becoming pregnant while taking NEXAVAR and for at least 2 weeks after stopping your treatment. Men and women should use birth control during and at least 2 weeks after NEXAVAR therapy. Talk with your doctor about effective birth control methods. Call your doctor right away if you become pregnant.
  • change in thyroid hormone levels. If you have differentiated thyroid carcinoma, you can have changes in your thyroid hormone levels when taking NEXAVAR. Your doctor should monitor thyroid hormone levels every month and may need to increase your dose of thyroid medicine.

The most common side effects with NEXAVAR include: diarrhea (frequent or loose bowel movements); tiredness; infection; hair thinning or patchy hair loss; rash; weight loss; loss of appetite; nausea; stomach (abdominal) pain; low blood calcium levels in people with differentiated thyroid cancer.

Tell your doctor if you have any side effects that bother you or do not go away. These are not all the possible side effects of NEXAVAR. Ask your doctor or pharmacist for more information.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information about NEXAVAR, please see the full Prescribing Information.